




# Immune signature, immune infiltration, and nontumor fraction

 Yue Wang  Da Yang

Updated date: Feb 22, 2021

 An abbreviated version of this protocol was published in Science Advances in Feb 2021

LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance

DOI: 10.1126/sciadv.abb3555

## Detailed protocol

Hi,  
The attached file includes the 68 immune signature enrichment and immune cell infiltration estimation across TCGA patients. Just let us know if there you have any further question.

Cheers,  
Yue

## Related files

 ImmuneSignaturesAndImmuneInfiltration.zip



**How to cite:** (Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used)

1. Wang, Y. and Yang, D. (2021). Immune signature, immune infiltration, and nontumor fraction. Bio-protocol Preprint. [bio-protocol.org/prep865](https://bio-protocol.org/prep865).
2. Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., Concha-Benavente, F., Fernandez, C., Li, S., Xie, W., Ferris, R. L., Kammula, U. S., Lu, B. and Yang, D. (2021). LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance . Science Advances 7(7). DOI: [10.1126/sciadv.abb3555](https://doi.org/10.1126/sciadv.abb3555)

**Copyright:** Content may be subjected to copyright.